Trial Profile

Phase I trial of sublingually administered buprenorphine/naloxone (OX 219) to determine commercial formulation and dose.

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 26 Sep 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Buprenorphine/naloxone (Primary)
Indications Pain
Focus Adverse reactions; Pharmacokinetics

Most Recent Events

26 Sep 2011 New trial record
21 Sep 2011 Results reported in an Orexo media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com